4DMedical Company Description

4DMedical Limited operates as a medical technology company in the United States and Australia.

The company engages in medical research technology and development of a non invasive respiratory imaging solution.

It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner.

The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research.

4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.

4DMedical Limited

Country	Australia
Founded	2012
Industry	Medical Devices
Sector	Healthcare
Employees	181
CEO	Andreas Fouras

Contact Details

Address: Melbourne Connect Carlton, VIC 3053 Australia
Phone	61 3 9545 5940
Website	4dmedical.com

Stock Details

Ticker Symbol	4DX
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000095416
SIC Code	7372

Key Executives

Name	Position
Julian Sutton B.Sc., C.F.A.	Chief Financial Officer and Executive Director
Matt Tucker	Chief Commercial Officer
Dr. Aidan Jamison B.E., Ph.D.	Senior Vice President of Engineering
Rachael Tenkaten	Senior Vice President of Product
Dr. Greg T. Mogel M.D.	Chief Medical Officer
David Hannes B.S., M.B.A.	Senior Vice President of Global Business Development
Hamish George B.Com., C.A.	Company Secretary